Purine and Pyrimidine Pathways as Antimalarial Targets
Malaria continues to plague the endemic regions of sub-Saharan Africa and Southeast Asia. With the current development of artemisinin resistance and a risk of failure of the current first line therapies, there is a growing need for novel antimalarials. Purine and pyrimidine metabolism in Plasmodium...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/83000 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1879164788359036928 |
|---|---|
| author | Minnow, Yacoba V. T. Schramm, Vern L. |
| author_browse | Minnow, Yacoba V. T. Schramm, Vern L. |
| author_facet | Minnow, Yacoba V. T. Schramm, Vern L. |
| author_sort | Minnow, Yacoba V. T. |
| building | IntechOpen |
| collection | Acceso abierto |
| description | Malaria continues to plague the endemic regions of sub-Saharan Africa and Southeast Asia. With the current development of artemisinin resistance and a risk of failure of the current first line therapies, there is a growing need for novel antimalarials. Purine and pyrimidine metabolism in Plasmodium is distinctly different from the human host, making these pathways valid targets for the development of novel antimalarials. Targeting key enzymes in these pathways with transition state analogs has provided high affinity inhibitors. Transition state mimicry can also provide selectivity for the parasite enzymes over the homologous enzymes of the human host. Resistance of Plasmodium parasites to current antimalarials will be compared to resistance development induced by transition state analogs inhibitors, a feature that may contribute to decreased resistance development. Tight binding and specificity of transition state analog inhibitors provide important features for novel antimalaria therapy with low toxicity and prevention of antibiotic resistance. |
| doi_str_mv | 10.5772/intechopen.106468 |
| first_indexed | 2026-10-15T21:39:54Z |
| format | Book Chapter |
| fullrecord | <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><identifier>intech-83000</identifier><datestamp>2022-08-16</datestamp>
<dc:title>Purine and Pyrimidine Pathways as Antimalarial Targets</dc:title>
<dc:creator>Yacoba V. T. Minnow</dc:creator>
<dc:creator>Vern L. Schramm</dc:creator>
<dc:subject>Health Sciences</dc:subject>
<dc:description>Malaria continues to plague the endemic regions of sub-Saharan Africa and Southeast Asia. With the current development of artemisinin resistance and a risk of failure of the current first line therapies, there is a growing need for novel antimalarials. Purine and pyrimidine metabolism in Plasmodium is distinctly different from the human host, making these pathways valid targets for the development of novel antimalarials. Targeting key enzymes in these pathways with transition state analogs has provided high affinity inhibitors. Transition state mimicry can also provide selectivity for the parasite enzymes over the homologous enzymes of the human host. Resistance of Plasmodium parasites to current antimalarials will be compared to resistance development induced by transition state analogs inhibitors, a feature that may contribute to decreased resistance development. Tight binding and specificity of transition state analog inhibitors provide important features for novel antimalaria therapy with low toxicity and prevention of antibiotic resistance.</dc:description>
<dc:publisher>IntechOpen</dc:publisher>
<dc:date>2022-08-16</dc:date>
<dc:type>Chapter, Part Of Book</dc:type>
<dc:identifier>https://www.intechopen.com/chapters/83000</dc:identifier>
<dc:identifier>doi:10.5772/intechopen.106468</dc:identifier>
<dc:language>en</dc:language>
<dc:relation>ISBN:978-1-80356-791-4</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/3.0/</dc:rights>
<dc:source>https://www.intechopen.com/books/11576 ; Malaria - Recent Advances and New Perspectives</dc:source>
</oai_dc:dc> |
| id | intech-83000 |
| institution | IntechOpen |
| isbn | 978-1-80356-791-4 |
| language | English |
| last_indexed | 2026-10-15T21:39:54Z |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | oai_dc |
| spelling | intech-830002022-08-16 Purine and Pyrimidine Pathways as Antimalarial Targets Yacoba V. T. Minnow Vern L. Schramm Health Sciences Malaria continues to plague the endemic regions of sub-Saharan Africa and Southeast Asia. With the current development of artemisinin resistance and a risk of failure of the current first line therapies, there is a growing need for novel antimalarials. Purine and pyrimidine metabolism in Plasmodium is distinctly different from the human host, making these pathways valid targets for the development of novel antimalarials. Targeting key enzymes in these pathways with transition state analogs has provided high affinity inhibitors. Transition state mimicry can also provide selectivity for the parasite enzymes over the homologous enzymes of the human host. Resistance of Plasmodium parasites to current antimalarials will be compared to resistance development induced by transition state analogs inhibitors, a feature that may contribute to decreased resistance development. Tight binding and specificity of transition state analog inhibitors provide important features for novel antimalaria therapy with low toxicity and prevention of antibiotic resistance. IntechOpen 2022-08-16 Chapter, Part Of Book https://www.intechopen.com/chapters/83000 doi:10.5772/intechopen.106468 en ISBN:978-1-80356-791-4 https://creativecommons.org/licenses/by/3.0/ https://www.intechopen.com/books/11576 ; Malaria - Recent Advances and New Perspectives |
| spellingShingle | Health Sciences Minnow, Yacoba V. T. Schramm, Vern L. Purine and Pyrimidine Pathways as Antimalarial Targets |
| title | Purine and Pyrimidine Pathways as Antimalarial Targets |
| title_full | Purine and Pyrimidine Pathways as Antimalarial Targets |
| title_fullStr | Purine and Pyrimidine Pathways as Antimalarial Targets |
| title_full_unstemmed | Purine and Pyrimidine Pathways as Antimalarial Targets |
| title_short | Purine and Pyrimidine Pathways as Antimalarial Targets |
| title_sort | purine and pyrimidine pathways as antimalarial targets |
| topic | Health Sciences |
| url | https://www.intechopen.com/chapters/83000 |
| work_keys_str_mv | AT minnowyacobavt purineandpyrimidinepathwaysasantimalarialtargets AT schrammvernl purineandpyrimidinepathwaysasantimalarialtargets |